Eosinophilic Granulomatosis With Polyangiitis (EGPA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Eosinophilic Granulomatosis With Polyangiitis (EGPA) Market Outlook

Thelansis’s “Eosinophilic Granulomatosis With Polyangiitis (EGPA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Eosinophilic Granulomatosis With Polyangiitis (EGPA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Eosinophilic Granulomatosis With Polyangiitis (EGPA) Overview

Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome or allergic granulomatosis and angiitis, is a rare and severe form of anti-neutrophil cytoplasm antibody-associated vasculitis characterized by eosinophil-rich granulomatous inflammation and small to medium-sized vessel vasculitis. It is an autoimmune disorder that affects multiple systems in the body and is often associated with bronchial asthma and tissue eosinophilia. The exact cause of EGPA is unknown, but it is triggered by various factors such as allergens, infections, vaccinations, and drugs. It typically affects people between the ages of 7 and 74, with no gender or ethnic predilection. The disease progresses through three stages: the prodromal stage, characterized by asthma or allergic rhinitis; the eosinophilic stage, characterized by excess circulating eosinophils and involvement of multiple organ systems; and the vasculitis phase, characterized by life-threatening vasculitis. The median age at the onset of EGPA is between 49 and 59 years, and about 90% of patients have a history of bronchial asthma. Differential diagnoses for EGPA include other small vessel vasculitides and eosinophilic disorders such as parasitic infections, drug allergies, haematological malignancies, eosinophilic pneumonia, and allergic bronchopulmonary mycosis.

• The prevalence of Eosinophilic Granulomatosis with Polyangiitis in the USA was estimated between 3.2 to 5.9 cases per million.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: